INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Core Viewpoint - INmune Bio Inc. is participating in the Maxim Healthcare Virtual Summit from October 15-17, 2024, to discuss its clinical-stage developments targeting neuroinflammation and Alzheimer's Disease [1][2]. Company Overview - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [2]. - The company has two main product platforms in clinical trials: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which includes XPRO, aimed at treating Mild Alzheimer's disease and potentially treatment-resistant depression and oncology in the future [2]. - The Natural Killer Cell Priming Platform, featuring INKmune™, designed to prime NK cells for cancer treatment, currently enrolling patients in a Phase I/II trial for metastatic castrate-resistant prostate cancer [2].